Acute myelogenous leukemia (AML) is the most common leukemia in adults with clonal proliferation of myeloid stem cells. Two or more cooperating mechanisms, namely block in differentiation, enhanced proliferation and resistance to programmed cell death, underlie this neoplastic transformation. Nonrandom, complete and partial deletions of chromosome 5 are common anomalies in AML. Using positional cloning strategies, we characterized an evolutionarily conserved candidate myeloid leukemia suppressor gene encoding sequence-specific single-stranded DNA binding protein 2 (SSBP2) from chromosome 5q13.3, a locus that is frequently deleted in AML. Recent studies in Drosophila and Xenopus demonstrate a pivotal role for SSBPs in embryonic differentiation. In mammals, SSBP2 is one of three highly related and ubiquitously expressed genes. Here, we identify frequent loss of SSBP2 protein expression in human AML cell lines using highly specific antibodies. Furthermore, inducible expression of SSBP2 in the AML cell line U937 leads to loss of clonogenicity, G1 arrest and partial differentiation. Remarkably, inducible expression of SSBP2 is accompanied by downregulation of C-MYC expression. Our findings are consistent with human SSBP2 being a novel regulator of hematopoietic growth and differentiation, whose loss confers a block in differentiation advantage to myeloid leukemic cells.
Introduction
Acute myelogenous leukemia (AML) is a malignancy in which myeloid progenitor cells with impaired differentiation properties and enhanced growth potential undergo clonal proliferation in the bone marrow. Reciprocal translocation between chromosomes resulting in gene fusions that confer a selective advantage to the leukemic clone is a common mechanism underlying AML pathogenesis. Frequently, loss of function of transcription factors that regulate normal myeloid differentiation is accomplished by chromosomal translocations (reviewed by Tenen, 2003) . In contrast to reciprocal translocations that generate chimeric gene products, very little is known about loss of critical target genes associated with the large chromosomal deletions in AML. For example, identification of candidate leukemia suppressor gene(s), associated with deletions of chromosome 5, a nonrandom anomaly seen in E9% of all AML and 50% t-AML (AML that arises secondary to therapy for other primary malignancies), has remained elusive. Taking advantage of an AML cell line ML3, which retains heterozygosity for all of chromosome 5q loci except at 5q13.3, our laboratory characterized the candidate leukemia suppressor gene sequence-specific single-stranded DNA binding protein 2(SSBP2), by a positional cloning approach (Castro et al., 2002) . Interestingly, gene expression profiles of primary myeloid leukemic progenitors by Affymetrix microarray analysis also revealed leukemia-specific downregulation of SSBP2 in nine out of 14 t-AML patients (Qian et al., 2002) .
SSBP2 is one of three related genes with a high level of identity in the deduced open-reading frames at 83% between SSBPs 2 and 3, 72% between SSBPs 3 and 4 and 73% between SSBPs 2 and 4. The founding member of this family, CSDP1 (the chicken ortholog of human SSBP3), was originally isolated as a partial cDNA in a Southwestern screen for proteins that bind to a chondrocyte-specific pyrimidine-rich DNAse I hypersensitive site in the a2A collagen promoter. CSDP1 showed exquisite specificity for pyrimidine-rich singlestranded mirror repeat elements in electrophoretic mobility shift assays (Bayarsaihan et al., 1998) . Although the function of CSDP1 in chicken a2A collagen is unknown, recent evidence demonstrates that SSBP proteins modulate LIM domain þ LDB1-(LIM domain binding protein 1) mediated differentiation in Xenopus and Drosophila by directly interacting with LDB1 (Chen et al., 2002; van Meyel et al., 2003) . Specifically, microinjection of the Drosophila or murine SSBP transcript enhances axis induction by LDB1 in combination with the Xenopus LIM-homeobox gene XLIM (Chen et al., 2002) . At present, there is no evidence that the SSBP-mediated differentiation is due to a direct transcriptional activity. Moreover, the relationship between the originally identified singlestranded DNA binding activity and the functional interaction with LDB1 is unknown at present.
In humans, the function of SSBPs remains unexplored, although all the three genes are ubiquitously expressed. All three deduced open-reading frames encode proteins of 36-38 kDa with a highly conserved LUFS amino-terminal domain and a glycine, prolinerich central domain. The LUFS domain comprising residues 22-75 in SSBP2 is so designated because of the high identity with similar domains in the plant transcription factor Leunig and Saccharomyces cerevisae transcription factor Flo8 (Castro et al., 2002) . Embedded within the LUFS domain is a 34-amino-acid novel motif LiSH, a motif in which a missense mutation is associated with Miller-Dieker lissencephaly, an inherited brain malformation syndrome (Emes and Ponting, 2001) . The glycine-proline-rich segment shows a weak similarity in the proline richness and periodicity to the evolutionarily conserved DNA binding 70-kDa subunit of RPA, the heterotrimeric protein that binds single-stranded DNA during replication and repair (Castro et al., 2002) .
A technical challenge for biochemical studies on SSBP proteins is the high identity between the three members. In this report, using highly specific antibodies against SSBP2, we demonstrate loss of expression in 50% of myeloid leukemic cell lines. Given the chromosomal localization and loss of expression, we reasoned that reexpression of SSBP2 would induce growth arrest and differentiation in AML cells. Regulatable expression of SSBP2 in the myelomonocytic leukemia cell line U937 abrogates clonogenicity, elicits G1 arrest and induces differentiation. Thus, our findings are consistent with an evolutionarily conserved role for SSBP2 in mediating differentiation. More importantly, loss of SSBP2 expression may underlie the impaired differentiation seen in human myeloid leukemia.
Results

Characterization of SSBP2-specific antibodies
As a first step towards characterizing the function of SSBP2, we generated polyclonal antibodies and validated their specificity. This was critical as the three related members SSBP2, SSBP3 and SSBP4 are ubiquitously expressed. In order to minimize crossreactivity, we raised antibodies to unique amino-terminal and internal peptides conjugated to keyhole limpet hemocyanin (KLH). Affinity-purified antibodies against the amino-terminal peptide were first tested on immunoblots containing FLAG epitope-tagged SSBP2 protein, immunoprecipitated by a monoclonal antibody against FLAG from COS-1 cells 48 h after transient transfection. The amino-terminal antibody detects a unique band at 45 kDa in cells transfected with FLAG-tagged SSBP2 in contrast to cells transfected with vector alone (Figure 1a) . Figure 1b further confirms the specificity of the amino-terminal antisera, as we detect a distinct band from whole-cell lysates of COS-1 cells expressing the protein transiently. Another sensitive means to assess the specificity was to compare the antisera raised against the amino-terminal (anti-N) and internal (anti-I) peptides, which do not share any sequence homology. As shown in Figure 1c , transiently expressed SSBP2 is detected at an apparent molecular mass of 45 kDa by both anti-N and anti-I antibodies. Furthermore, we detected a 3-4 fold stronger signal with the antibody against the internal peptide. To test whether this was due to crossreactivity of the anti-I antisera with endogenous SSBP3 protein that is 83% identical to SSBP2, with 69% identity in the I-peptide region, a comparison between the two proteins was performed. Figure 1d further validates the specificity of both the antibodies towards SSBP2 as there is no crossreactivity with SSBP3 even under conditions of overexpression. Anti-FLAG anti-N F la g B P 2 F la g B P 3 F la g B P 2 F la g B P 3
anti-I F la g B P 2 F la g V E C F la g V E C F la g B P 2 a b c d Additionally, crossreactivity of the anti-I antibodies with SSBP4 may also be excluded since the sequence identity between the two proteins in the internal peptide region was only 43%. Detection of both the FLAGtagged SSBP3 and SSBP2 with the anti-FLAG monoclonal bodies served as control. Furthermore, the antibodies against the internal peptide are of very high affinity as the protein could be readily detected at an antibody dilution of 1 : 10 000. Because of this, we routinely use the anti-I antisera to detect endogenous SSBP2.
Of note is the finding that SSBP2 migrates at an apparent molecular mass of 45 kDa, although the deduced molecular weight is 39 kDa. This may be due to the high proline content at 16.6%. The specificity of the antibodies was further verified by expression constructs lacking the pro-rich domain that had normal mobility on sodium dodecyl sulfate (SDS)-PAGE (H Liang and L Nagarajan, unpublished results). More importantly, expression constructs encoding the deduced open frame migrated in a manner identical to endogenous protein from many cell types.
SSBP2 protein expression is lost frequently in acute myeloid leukemic cell lines
Northern analyses suggested varied SSBP2 transcript levels in AML cell lines with no expression in HL60 cells, reduced expression from the haplo-insufficient ML3 cells and abundant expression in KG1 cells consistent with the genotypic and phenotypic heterogeneity in AML (Castro et al., 2002) . To examine whether this was reflected at the protein level, we screened eight myelogenous leukemia cell lines with and without deletions of chromosome 5q (Figure 2 ). The reduced protein levels in ML3 cells are consistent with the hemizygosity of the gene, since the truncated sequences are not readily detected in these cells. It is interesting to note that SSBP2 expression is undetectable in HL60, HEL, TF1 and U937 cells. Of these, the cell line HL60 is hemizygous for the SSBP2 gene. The status of the SSBP2 gene in the erythroleukemia cell lines HEL and TF1 as well as AML cell lines U937 and KG1 are unknown, although all of these cell lines harbor unbalanced translocations of chromosome 5q. K562 and BV173 cells that are derived from chronic myelogenous leukemia patients in blast crisis who have no aberrations of chromosome 5 express abundant SSBP2 protein. Overall, this screen confirms loss of SSBP2 expression in 50% of the cell lines. The protein levels also reflect the transcript levels measured by Northern analysis with no transcripts in U937, HL60, HEL and TF1 (Castro et al., 2002; H Liang et al., unpublished results) .
Generation of AML cell lines with inducible expression of SSBP2
Lack of readily detectable SSBP2 expression in the myelomonocytic leukemia cell line U937 provided an excellent system to investigate the function of SSBP2.
Inducible expression of myelomonocytic transcription factors can cause changes in growth and differentiation characteristics in this system (Boer et al., 1998; Bromleigh and Freedman, 2000; Caslini et al., 2000; Burel et al., 2001; McConnell et al., 2003) . Using the U937T cells expressing the tetracycline-controlled transactivator protein (tTA), we generated inducible clones designated BP2-28, BP2-30 and BP2-37. The three clones were derived from independent electroporations and are likely to represent independent sites of plasmid integrations ( Figure 3 ). The inducibility of SSBP2 is similar to that seen with other regulatory molecules, namely MLL, HOXA10, AML-ETO and PLZF seen in the U937T system (Boer et al., 1998; Bromleigh and Freedman 2000; Caslini et al., 2000; Burel et al., 2001; McConnell et al., 2003) . Clones BP2-28 and BP2-30, which showed good inducibility with minimal leakiness, were used in further studies.
Regulatable expression of SSBP2 causes growth arrest and loss of clonogenicity in U937 cells
To determine whether inducible expression of SSBP2 causes direct growth arrest and differentiation or an apoptotic response in U937 cells, we examined the growth kinetics of clones BP2-28 and BP2-30 in the presence and absence of tetracycline. A vector-transfected control U937T clone was used as control. All the three clones proliferated exponentially in the presence of tetracycline. More importantly, all three clones attained similar cell density on day 6 (Figure 4a , top panel). In contrast, induction of SSBP2 expression in both the clones BP2-28 and BP2-30 resulted in a significant decrease in cellular proliferation between days 3 and 6. The vector-transfected U937T cells, however, exhibit exponential growth for 4 days and continue to proliferate for 6 days ( Figure 4b , bottom panel). Neither trypan blue staining nor assays for apoptosis indicated cell death during the 6-day period in cells induced to express SSBP2. These findings are consistent with SSBP2 being a mediator of growth arrest in the myelomonocytic leukemia cells. A decrease in proliferative potential may also be reflected in the ability to form colonies under clonogenic conditions in semisolid medium as growth-arrested cells will not divide. In order to examine this possibility, we determined the clonogenicity of the Vec, BP2-28 and BP2-30 cells. Under the methyl cellulose culture conditions, the clonogenicity was >75% for both the parental Vec, BP2-28 and BP2-30 cells in the presence of tetracycline unlike BP2-28 and BP2-30 clones that were reduced to 10 and 14%, respectively, in the absence of tetracycline ( Figure 4a , Table 1 ). These findings demonstrate that ectopic expression of SSBP2 abrogates clonal proliferation of myeloid leukemic cells. Conversely, downregulation of SSBP2 expression may confer a proliferative advantage to the leukemic progenitor during the evolution of AML.
SSBP2-induced growth arrest is accompanied by loss of C-MYC expression
CSDP, the founding member of the SSBP gene family, was isolated as a protein that binds single-stranded sequences from a nuclease hypersensitive site in the chicken collagen a2A collagen promoter. A similar pyrimidine-rich, nuclease hypersensitive site also regulates the human C-MYC gene expression, although the significance of SSBP binding to either promoter is unknown at present. Thus, we examined C-MYC expression at both RNA and protein levels in BP2-30 cells 48 h after tetracycline withdrawal. Figure 5a (top panel) shows that the C-MYC transcript levels are dramatically reduced 48 h after the withdrawal of tetracycline. This is also reflected in the absence of c-myc protein in cells expressing SSBP2 (Figure 5a , bottom panel). Cultures grown in the presence of tetracycline as well as the cells at 0 h prior to tetracycline depletion served as positive controls. When the kinetics of C-MYC expression was examined every 6 h during the first 24 h of induction, the levels of C-MYC expression were downregulated concomitant with SSBP2 expression (Figure 5b ). The levels of SSBP2 increased between 12 and 18 h after tetracycline withdrawal, during which period the C-MYC expression was reduced. These findings allow us to conclude that the growth arrest and loss of clonogenicity resulting from inducible expression of SSBP2 are associated with loss of C-MYC expression.
SSBP2 expression induces cell cycle arrest in the G1 phase Downregulation of C-MYC would result in an arrest in the G1 phase of the cell cycle. However, given the unknown function of SSBP2, we examined whether the growth-arrested cells seen in Figure 4 were blocked in G1 as well as other phases of the cell cycle. Fluorescence-activated cell sorting (FACS) analyses of cells grown in the presence or absence of tetracycline for 4 days are depicted in Figure 6 . Vec cells that stably express the pTRE vector showed very similar distribution of cells in G1, S and G2 phases both in the presence and absence of TET. After 4 days of SSBP2 induction, however, the percentages of cells in the G1 phase in clones BP2-28 and BP2-30 are 83 and 84%, respectively. The increase in the G1 phase is accompanied by a 70% decrease in cells in the S phase. There are no gross differences in the fraction of cells in G2/M. Additionally, the G1 arrest after 4 days of SSBP2 expression is not accompanied by apoptosis as seen by the absence of strong sub-G1 population, that is, cells with less than 2 Â DNA content seen as FL2-A values of less than 60.
SSBP2 expression induces partial differentiation of U937 cells
Whether the SSBP2-mediated growth arrest elicited a differentiation response in U937 cells was examined next. CD11b and CD14, cell surface markers whose expression is enhanced in myelomonocytic progenitors upon differentiation to more mature cells, were studied in cells expressing SSBP2 for 4 days. As shown in Figure 7 , cells expressing SSBP2 show an increase in the expression of both CD11b and CD14 by an order of magnitude when assayed by flow cytometry. To further characterize whether the cells gave rise to terminally differentiated granulocytes or monocytes/macrophages, cytospin preparations of cells induced to express SSBP2 were examined for morphological changes by WrightGiemsa staining. Interestingly, cells expressing SSBP2 showed partially differentiated macrophage morphology with increase in cell size, cytoplasmic to nuclear ratio and vacuolated cytoplasm (Figure 7b ).
Discussion
Members of the novel SSBP gene family are evolutionarily conserved modulators of differentiation. In this report, we investigated the expression and function of SSBP2 protein by generating highly specific antibodies. Lack of SSBP2 expression in four out of the eight AML cell lines tested suggests a potential proliferative or survival advantage for leukemic progenitors with More importantly, the growth arrest is accompanied by partial differentiation of the precursor cells in the monocytic lineage, suggesting a critical role for SSBP2 in growth arrest prior to differentiation.
AML and impaired differentiation
AML is a malignancy that represents clonal proliferation of a myeloid progenitor cell with growth, survival advantage and impaired differentiation function. In normal hematopoiesis, six distinct terminally differentiated cell types, namely erythrocytes, megakaryocytes, granulocyte, monocytes/macrophages, basophils and eosinophils, arise from a well-organized hierarchy of myeloid stem cells and committed progenitors. The myeloid differentiation program, mediated by specific transcription factors, exhibits a level of redundancy and fail-safe mechanisms, but it is also stringently regulated (reviewed in Cantor and Orkin, 2001) .
A large body of evidence accumulated within the past few years demonstrates inactivating mutations and haploinsufficiency in transcription factors that regulate commitment to specific lineages in AML. Inactivating heterozygous mutations in AML1, CEBP alpha, PU.1 and GATA-1 are associated with a small subset of AML. These subtle mutations are unique to distinct AML entities, classified on the basis of putative myeloid/monocytic or megakaryocytic maturation properties (reviewed in Tenen, 2003) . Typically, these Figure 6 SSBP2 expression results in G 1 cell cycle arrest in U937 cells. BP2-28, BP2-30 and Vec cells were cultured for 4 days in the presence or absence of tetracycline. The peak filled in light red to the left denotes diploid cells in G1, the red peak to the right is G2 and the area marked by the hatched blue line denotes diploid cells in the S phase. The green area denotes aggregates that were excluded from the analysis. Flow cytometry was performed on nuclei stained with propidium iodide. The percentage of cells in different phases of the cell cycle was determined using ModFitLT software program. In a similar experiment, the G1 and S distributions of BP2-28 and BP2-30 cells grown for 72 h in the absence of tetracycline were 56, 36.8% and 65.28 and 7%, respectively mutations are not accompanied by gross chromosomal alterations or rearrangements of the genomic locus. Deletions of chromosome 5q, on the other hand, are recurrent anomalies seen in AML with phenotypic characteristics both myeloid/monocytic or erythroid leukemia. Thus, the loss of a regulatory gene from chromosome 5 is likely to contribute to cell cycle arrest and differentiation in the myelomonocytic, megakaryocytic and erythroid lineages. Such a notion is supported by the lack of SSBP2 expression in AML cells arrested in the granulocyte/macrophage progenitor stage (HL60, U937) as well as erythroid lineage (HEL and TF1) as shown in Figure 2 . Furthermore, our previous studies demonstrated that deletions of chromosome 5q13-14 were commonly found in patients with loss of chromosome 17p and mutations of the TP53 gene. Unbalanced translocation between 5q and 17p appears to be a common mechanism for physical loss of chromosome 5q and 17p loci (Castro et al., 2000) . It is interesting to note that six of the eight cell lines, namely TF1, HEL, ML3, HL60, KG1 and U937, shown in Figure 2 harbor inactivating mutations or deletions in the TP53 gene. K562 cells do not express the TP53 protein. In contrast, the BV173 cells, which express high levels of SSBP2, have a functional TP53 gene pathway (Bi et al., 1992; Rizzo et al., 1998; Castro et al., 2000; Fleckenstein et al., 2002) . These correlations provide a basis for additional mechanistic studies to dissect the functional cooperation between the coordinated loss of TP53 and SSBP2 expression in refractory AML. Future studies on SSBP2 protein expression in primary leukemic blasts in patients 
SSBP2, a modulator of cell cycle
The downregulation of C-MYC expression associated with cell cycle arrest of myelomonocytic cells U937 demonstrates for the first time a direct role for human SSBP in regulating growth ( Figure 5 ). These findings are also in agreement with the overexpression of C-MYC in t-AML patients with downregulated SSBP2 by gene expression profiling (Qian et al., 2002) . Interestingly, >80% of C-MYC transcription is regulated by nuclease hypersensitive element, NHE III1, located À142 to À115 upstream of the P1 transcriptional start site with a potential to form a rare intramolecular DNA structure, the G-quadruplex in the noncoding strand. Recent evidence suggests that mutations in the G-quadruplex silencer element underlie C-MYC overexpression in colon cancer (Grand et al., 2004) . The possibility that SSBP proteins bind the complementary pyrimidine-rich single strand to stabilize the G-quadruplex remains to be examined. In such a scenario, SSBPs may directly repress C-MYC expression. We are currently examining whether the single-stranded binding activity of SSBP2 has mechanistic ramifications on C-MYC transcription. Although the low binding affinity of single-stranded DNA proteins has been a technical limitation for such studies in the past, recent advances in protein-protein crosslinking prior to chromatin immunoprecipitation may alleviate this problem. Nonetheless, does SSBP2 primarily induce cell cycle arrest or monocytic differentiation, the consequence of which is a secondary G1 arrest? The kinetics of C-MYC expression shown in Figure 5b demonstrate loss of C-MYC expression when SSBP2 is induced. Additionally, a preliminary screen for global screen expression profile in BP2-30 cells demonstrates loss of C-MYC expression and not an upregulation of transcription factors known to induce monocytic differentiation. Conversely, induction of CEBP alpha in the U937 cells that undergo granulocytic differentiation is not accompanied by SSBP2 expression (H Liang and L Nagarajan, unpublished results). Thus, our findings are most consistent with a cell cycle arrest under the conditions and levels of SSBP2 induction in the U937T system. The partial differentiation in the monocytic lineage is secondary to the observed growth arrest.
SSBP2, a regulator of LIM domain transcription factors
SSBPs modulate the evolutionarily conserved differentiation function of LIM domain proteins and their interacting partners LDB1. A number of LIM domaincontaining transcription factors are critical for myeloid stem cell proliferation. hLIM-1, a LIM/Homeobox gene, is frequently expressed in myeloid leukemia (Dong et al., 1997) . LMO2, originally isolated due to its activation in T-cell leukemia, is a key regulator of normal hematopoietic differentiation. More recent evidence suggests that LMO2 acts as a bridge in assembling a multiprotein transcription complex comprising tal-1, ldb1 and GATA-1 in erythroid cells (Wadman et al., 1997; Xu et al., 2003) .
SSBP2, a multifunctional protein
Multiple lines of evidence suggest that SSBP proteins may participate in a number of different mechanisms. First, in Drosophila, SSDP/SSBP null alleles are cell lethal in the wing disc, whereas null alleles for chip the Drosophila ortholog of LDB1 or ap, the Drosophila LimHomeodomain factor are not. The possibilities that SSBPs function through other pathways mediated by direct interaction with other regulatory proteins or direct DNA binding remain to be explored. A mammalian two-hybrid screen suggests that SSBPs may directly bind LIM domain factors (Suzuki et al., 2001) . Second, all three mammalian SSBPs contain the LiSH domain (spanning residues 18-50 in SSBP2) in the aminoterminus. The modular LiSH domain, thus designated because of the mutation in hereditary lissencephaly, is conserved in many proteins that bind and interact with cytoskeleton. Thus, SSBP2 may function by direct interaction with cytoskeletal elements and alter signal transduction. SSBP2 interactions with cytoskeletal proteins may regulate cell motility, protein transport, chromosome segregation and cytokinesis. Finally, the pyrimidine-rich mirror (single-stranded) DNA and potential RNA binding property of SSBP2 may confer unique regulatory functions. Our preliminary results suggest that mammalian SSBP2 also binds singlestranded pyrimidine elements similar to that reported for CSDP, the chicken ortholog of SSBP3 (S Samanta et al., unpublished results). Another important question that arises from our studies is whether other members of the family, that is, SSBPs 3 and 4, do not compensate for loss of SSBP2 expression. The findings reported here taken together with the detection of leukemia-specific loss of SSBP2 expression and not SSBPs 3 and 4 (Qian et al., 2002) as well as embryonic lethality of null mice (van Meyel et al., 2003) suggest unique functions for SSBP2. More importantly, the stoichiometry between the LIM proteins LDB1 and SSBP may be critical in eliciting the appropriate differentiation response. Thus, SSBP2 may be analogous to an important tumor suppressor b-catenin with critical roles in cell-cell interactions as well as transcription. In short, the findings reported here on SSBP2-mediated growth arrest and differentiation of AML cells provides the first functional proof for the leukemia suppressor activity for a gene localized to a critical region of loss on 5q13.3 and downregulated in patients with loss of 5q. (Hu and Maity, 2000) . pCMV2-FLAG-SSBP3 was generated with primers unique for SSBP3. All plasmid constructs were verified by double-stranded sequencing.
Materials and methods
Plasmids
Cell lines
Several acute myelogenous leukemic cells with anomalies of chromosome 5q were used in the present study. Of these, TF1, HEL (erythroleukemia), HL60 and U937 (myelomonocytic leukemia) harbor unbalanced translocations involving chromosome 5q. KG1 (AML) cells are monosomic for chromosome 5 and ML3 (AML) cells carry a del (5)(q13-q35) chromosome and a der (3) chromosome with insertion of (5)(q13-35) material. Additionally, K562 (Philadelphia chromosome-positive (Ph þ ) chronic myelogenous leukemia in erythroid blast crisis) and BV173 (Ph þ chronic myelogenous leukemia in lymphoid blast crisis) were also included. The cells were cultured according to their growth requirements in humidified air containing 5% CO 2 at 371C. ML-3, HEL, K562, BV173, HL60 and U937cells were grown in RPMI 1640 medium with 10% fetal bovine serum (FBS), KG1 in IMDM with 20% FBS. The factor-dependent cell line TF1 was grown in RPMI 1640 with 10% FBS þ 5 ng/ml GM-CSF FBS þ 5.
Generation of an AML cell line expressing SSBP2 under inducible conditions U937T, a kind gift from Dr G Grossveld. (Boer et al., 1998) , are derived from myelomonocytic U937 cells by stable transfection with pTET-VP16PURO fusion gene under the control of a tetracycline-inducible promoter. U937T cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 0.5 mg/ml of puromycin (Sigma, St Louis, MO, USA) at 371C with 5% CO 2 . A total of 1 Â 10 7 cells in 0.5 ml of additive-free RPMI 1640 medium were electroporated in a gene pulser apparatus (Bio-Rad laboratories, Hercules, CA, USA) with 20 mg of ScaI-linearized pTRE-FLAG-BP2 plasmid together with 2.2 mg of BglI-linearized pTK-Hyg plasmid at 960 mF, 250 V in 4.0 mm cuvettes. The cells were diluted 20 times after pulse with complete medium containing 2.0 mg/ml of tetracycline (TET) and plated into a 96-well plate at 10 5 cells/well. After 48 h, the cells were selected in medium containing hygromycin (0.3 mg/ml), puromycin (0.5 mg/ml) and TET (2.0 mg/ml). The hygromycin-resistant clones were selected after 2-3 weeks by plating cells at 0.2 cells/well (96-well plate) in selection medium containing 10% conditioned medium. The resulting cultures were expanded and screened by immunoblotting. The selected clones, which expressed SSBP2 upon TET withdrawal, were designated BP2-28, BP2-30 and BP2-37. For control, U937T cells electroporated with pTRE-FLAG and pTK-Hyg plasmids underwent the same selection scheme. One of these clones designated Vec is used in the present study.
Transient transfection assays
NIH3T3 or Cos-1 cells were plated at a density of 2 Â 10 5 per well in six-well plate a day prior to transfection. Transient transfections were performed using the LipofectAMINE kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. Cells were harvested after 48 h of transfection.
Generation of antisera
Unique amino-terminal (MYGKGKSNSSAVPS) and internal (DNMYTLMNAVPPGPNR) peptides were synthesized in our institutional core facility. The peptides were conjugated to KLH and used to immunize rabbits (Bethyl Laboratories, Montgomery, TX, USA). Affinity-purified antibodies were stored at a concentration 1.467 mg/ml for the amino-terminal epitope and 1.13 mg/ml for the internal epitope.
Immunoprecipitation
Cos-1 cells grown in 100 mm dish were lysed with 1 ml of icecold RIPA buffer (150 mM NaCl, 1.0%. NP-40, 0.5% DOC (sodium deoxycholate), 0.1% SDS, 50 mM Tris (pH 7.5), 5 mg/ml leupeptin, 8 mg/ml aprotinin, 1 mM PMSF, 0.7 mg/ml pepstatin A and 1 mM EDTA (pH 8.0)). 500 ml of lysates was precleared by incubation with prebled rabbit serum followed by incubation with protein G-agarose beads for 1 h at 41C. M2 anti-flag monoclonal antibody (5 mg) (Sigma, St Louis, MO, USA) was added to precleared lysate and incubated overnight at 41C. 20 ml of protein G-agarose beads was added to the immune complexes and incubated for 1 h at 41C. After four washes with NET-N buffer (100 mM NaCl, 1 mM EDTA (pH 8.0), 20 mM Tris (pH 8.0), 0.2% NP-40, 5 mg/ml leupeptin, 8 mg/ml aprotinin, 1 mM PMSF, 0.7 mg/ml pepstatin A), the precipitated proteins were eluted in 20 ml of 2 Â SDS loading buffer (100 mM Tris (pH 6.8), 200 mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and then resolved by 4-12% NuPAGE gel (Invitrogen, Carlsbad, CA, USA).
Immunoblotting
Cells were lysed in 1% Triton X-100, 250 mM NaCl, 20 mM Tris (pH 7.4) and 2 mM EDTA with proteinase inhibitors. The lysates were denatured in 4 Â sample buffer at 701C for 10 min, resolved in 4-12% NuPAGE gel (Invitrogen, Carlsbad, CA, USA) and transferred onto PVDF membrane. The membrane was blocked in 5% nonfat milk in PBS buffer for 2 h at room temperature and probed with the primary antibody at room temperature for 1 h in PBS-T buffer containing 2% nonfat milk and 0.5% tween-20. This was followed by washing the membrane four times in PBS-T (0.5% Tween-20). The membrane was incubated with appropriate horseradish peroxidase-conjugated goat anti-rabbit secondary antibody at room temperature for 45 min, followed by washing the membrane four times in PBS-T (0.5% Tween-20) for 5 min each time, with the last wash for 15 min. The horseradish peroxidase conjugate was detected by chemiluminescence with the ECL-plus kit and autography (Amersham Biosciences, Piscataway, NJ, USA).
Northern blotting
Total RNA was isolated from BP2-28 cells induced to express SSBP2 by withdrawal of tetracycline for 48 h. Total RNA (10 mg) was electrophoresed in a 1.2% denaturing formaldehyde gel and transferred to Hybond N membrane (Amersham Biosciences, Piscataway, NJ, USA). After prehybridization, the membrane was hybridized with a full-length human C-MYC cDNA plasmid SP65mycIIA WT (a kind gift from Dr C Dang) labeled with [g-32 P]dCTP by Random Primed DNA Labeling kit (Roche Applied Science, Indianapolis, IN, USA) overnight in 50% formamide, 10 Â Denhardt's, 5 Â SSPE, 100 mg/ml ssDNA at 421C. The blot was washed twice for 20 min each time at 651C in 0.1 Â SSC in 0.1% SDS and finally for 30 min at 651C in 0.05 Â SSC-0.1% SDS, and the signal was detected by autography. The blot was stripped and reprobed with a cDNA for b-actin using the same protocol.
Growth measurements, clonogenicity and differentiation
For growth curve analysis, BP2-28, BP2-30 and Vec cells were washed once with complete medium without antibiotics and seeded at 2 Â 10 4 /ml in the complete medium with 0.5 mg/ml of puromycin, 300 mg/ml of hygromycin, plus or minus 2 mg/ml of tetracycline. 100 ml aliquots of cells was assayed in quadruplicate with CellTiter 96 Aqueous nonradioactive cell proliferation assay kit (Promega Corporation, Madison, WI, USA) once a day for 6 days. Each experiment was repeated three times. For clonogenicity analysis, BP2-30 and Vec were cultured in media containing 79.1% RPMI 1640, 0.9% methycellulose (StemCell Inc., Vancouver, BC, Canada) and 20% FBS with 0.5 mg/ml of puromycin and 0.3 mg/ml of hygromycin plus or minus tetracycline 2 mg/ml at a cell density of 100 cells/well in six-well plates. Colonies from duplicate wells were photographed on day 10. To examine cell differentiation, BP2-28 and Vec cells were seeded in RPMI 1640 medium at 1 Â 10 3 cells/ml containing 0.5 mg/ml of puromycin, 0.3 mg/ml of hygromycin, plus or minus TET. Cells were cytospun onto aminoalkylsilane-coated slides (Sigma Chemical Company, St Louis, MO, USA) after 12 days and then stained by Hema 3 Stain kit (Fisher Scientific, Pittsburgh, PA, USA) to visualize morphological changes.
FACS and cell cycle analysis
Aliquots of (2 Â 10 5 ) BP2-28, BP2-30 and Vec cells were collected on day 4 after TET withdrawal and washed once with PBS and then resuspended in 1 ml of PBS. Cells were fixed by adding 4 ml of ice-cold absolute ethanol into 1 ml of cell suspension while vortexing. After fixation at À201C for 15 min, cells were spun out of fixative and incubated in 1 ml of PBS containing 50 mg/ml of propidium iodide and 100 mg/ml of RNase A at 371C for 30 min. The DNA contents were analysed by flow cytometry in a BD FACS Calibur (Becton Dickinson, Palo Alto, CA, USA) using the Mod FitLT (Version 3.1) software. For cell surface immunostaining, cells were washed twice and resuspended in 75 ml of PBS containing 1% BSA. 2 ml of FITC-conjugated CD11b and PE-conjugated CD14 antibodies (Caltag Laboratories, Burlingame, CA, USA) were added and the cells were incubated on ice for 1 h in the dark. The cells were washed twice to remove unbound antibodies and resuspended in 1 ml of PBS with 1% BSA and subjected to FACS analysis. Approximately 10 4 events were scored for each sort.
